Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).

BACKGROUND: Direct antiviral agents (DAAs) became available in France in 2014 for the treatment of chronic hepatitis C (CHC) in patients with severe fibrosis (prioritized access); in 2017, DAAs became available to all CHC patients (universal access). We evaluated the impact of extending DAA availabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pol, Stanislas, Fouad, Fayssoil, Lemaitre, Magali, Rodriguez, Ingrid, Lada, Olivier, Rabiega, Pascaline, Benabadji, Elias, Roudot-Thoraval, Françoise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671622/
https://www.ncbi.nlm.nih.gov/pubmed/34950924
http://dx.doi.org/10.1016/j.lanepe.2021.100281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671622/
https://www.ncbi.nlm.nih.gov/pubmed/34950924
http://dx.doi.org/10.1016/j.lanepe.2021.100281

Ejemplares similares